

Response to July 6, 2005, Office Action
Atty Dkt No. 03-0185
Application No. 10/759,555

REMARKS

In the Office Action under reply, claims 1-33 are pending. The claims have been rejected as follows:

1. Under 35 U.S.C. §112, second paragraph, as lacking sufficient antecedent basis (claims 10, 12, 14, 16, 18, 20, 25, 27, 29, and 32); and
2. Under 35 U.S.C. §112, first paragraph, as lacking enabling disclosure in the specification (claims 1 and 30-33).

Additionally the Examiner has objected to claims 2-9, 11, 13, 15, 17, 19, 21-24, 26, and 28 as dependent upon a rejected base claim but has indicated that these claims would be allowable if rewritten in independent form.

In the present amendment, claims 1, 2, 12, 14-18, 20, 23, 25-27, 29, and 32 have been amended. Thus, claims 1-33 remain pending in the application. The Examiner's rejections and objections are addressed in full by the above-amendments.

THE AMENDMENTS TO THE CLAIMS

Claim 1 has been amended to specify the V is -N< and that T is oxygen or sulfur. Claim 2 has been amended to remove the resulting redundancy.

Claims 10, 12, 14, 16, 18, 20, 23, 25, 27, and 29 have been amended to remove the language "an isomer of the compound" in the preamble.

Claims 15, 17, 26, and 27 have been amended to correct minor typographical errors in the naming and/or misidentification of the R substituents.

Claim 32 has been amended to correctly depend from claim 30.

No new matter has been added.

Response to July 6, 2005, Office Action
Atty Dkt No. 03-0185
Application No. 10/759,555

REJECTION UNDER 35 U.S.C. §112, SECOND PARAGRAPH

The Examiner has rejected claims 10, 12, 14, 16, 18, 20, 25, 27, 29, and 32 under 35 U.S.C. §112, second paragraph. Claims 10, 12, 14, 16, 18, 20, 25, 27, and 29 have been rejected for their use of the expression "an isomer of the compound...". As the claims have been amended to remove this language, the rejection, as it pertains to them, is now moot. Claim 32 has been similarly rejected as it improperly depends from claim 31 rather than claim 30. This too has been corrected by the above amendments. Given that all the Examiner's concerns have been addressed, Applicants submit that the rejection is now moot and respectfully request that it be withdrawn.

REJECTION UNDER 35 U.S.C. §112, FIRST PARAGRAPH

The Examiner has rejected claims 1 and 30-33 under 35 U.S.C. §112, first paragraph, based on an allegedly lack of enabling disclosure specifically referencing a lack of enablement for those compounds wherein V is CH= or NHCH=. While not necessarily agreeing with the Examiner's position and in the interest of expediting prosecution, Applicants have amended claim 1 to specify that V is -N<, a substituent that has been clearly indicated by the Examiner as enabled. Given this amendment, Applicants submit that the rejection is now moot and respectfully request that it be withdrawn.

THE OBJECTION TO THE CLAIMS

The Examiner has indicated that claims 1, 2, 12, 14-18, 20, 23, 25-27, 29, and 32 are objected to, but would be allowable if rewritten in independent form. Applicants respectfully submit that the above amendments and accompanying remarks render the claim objections moot, and all claims are now in a condition for allowance.

Response to July 6, 2005, Office Action
Atty Dkt No. 03-0185
Application No. 10/759,555

CONCLUSION

For the foregoing reasons, Applicants submit that the claims are in condition for allowance. A Notice of Allowance is requested, and a prompt mailing thereof would be much appreciated.

Should the Examiner have any questions, he is invited to contact the undersigned attorney at (650) 384-8755.

Respectfully submitted,

Date:

8/23/05

By:

J. Elin Hartum
Reg. No. 43,663

CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, CA 94304
Phone: (650) 384-8755
Fax: (650) 475-0359

SALEGALCVT\Patent\Docs\03-0185\03-185-US\Resp to 7-6-05 OA.doc